August 2024

[Article Publication] Dr. Chung-Teh Lee, Teresa Huang, Ankwei Chen, Oli Wong and Sally Yang provided an update to their

August 2, 2024

Our attorneys Dr. Chung-Teh Lee, Teresa Huang, Ankwei Chen, Oli Wong and Sally Yang have updated their work on the "Pharmaceutical Intellectual Property and Competition: Taiwan" article that is published on Lexology In-Depth.  The article provides an overview of pharmaceutical product regulations in Taiwan, including the new drug approval process, the patent linkage system and the interactions with competition law.  The update for 2024 includes the new parallel review system that would allow the pharmaceutical product manufacturer to simultaneous apply for reimbursement recommendations while applying for inspection and registration of its new drug, the newly passed legislation on regenerative medicine, and the relaxing of merger filing rules for foreign enterprises setting up or operating a joint venture outside of Taiwan.

Explore the full article: https://www.lexology.com/account/activatetempaccess/?sl=2JDsGNt4YQ9CCiLqQXPs8LU1HlI



Lexology In-Depth - Pharmaceutical Intellectual Property and Competition - Taiwan

Lexology In-Depth - Pharmaceutical Intellectual Property and Competition

本网站上所有资料内容(「内容」)均属理慈国际科技法律事务所所有。本所保留所有权利,除非获得本所事前许可外,均不得以任何形式或以任何方式重制、下载、散布、发行或移转本网站上之内容。

所有内容仅供作参考且非为特定议题或具体个案之法律或专业建议。所有内容未必为最新法律及法规之发展,本所及其编辑群不保证内容之正确性,并明示声明不须对任何人就信赖使用本网站上全部或部分之内容,而据此所为或经许可而为或略而未为之结果负担任何及全部之责任。撰稿作者之观点不代表本所之立场。如有任何建议或疑义,请与本所联系。

作者